[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343103-105":59,"doc-detail-343103-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-tumor-dna-mutation-analysis-advances-in-its-application-for-early-diagnosis-of-hepatocellular-carcinoma-and-therapeutic-efficacy-monitoring","Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring","","Circulating tumor DNA (ctDNA) detection and sequencing have become a major focus in cancer research, especially for early diagnosis of hepatocellular carcinoma (HCC) and for monitoring therapeutic efficacy. ctDNA consists of cell-free DNA fragments carrying tumor-specific genetic and epigenetic alterations, enabling a non-invasive diagnostic and prognostic strategy. ctDNA concentration is reported higher in patients than in healthy individuals, and sequential analysis during primary or adjuvant therapy can reveal resistance and recurrence before visible tumor changes. Ongoing work addresses sequencing accuracy, sample-throughput burden, and sources of variability in linking ctDNA levels to tumor burden.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumor-dna-mutation-analysis-advances-in-its-application-for-early-diagnosis-of-hepatocellular-carcinoma-and-therapeutic-efficacy-monitoring/343103/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-mutation-analysis-advances-in-its-application-for-early-diagnosis-of-hepatocellular-carcinoma-and-therapeutic-efficacy-monitoring/343103.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is circulating tumor DNA (ctDNA) and why is it useful for HCC?","Question",{"text":112,"@type":113},"ctDNA refers to cell-free DNA fragments released from tumor cells into the bloodstream. It carries tumor-specific genetic and epigenetic alterations, supporting non-invasive diagnosis, prognosis, and monitoring in hepatocellular carcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does sequential ctDNA analysis help during treatment?",{"text":117,"@type":113},"Sequential ctDNA testing in patients receiving primary or adjuvant therapy can detect treatment resistance and recurrence earlier than visible morphological tumor changes, enabling faster adjustment of treatment strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges remain for ctDNA mutation analysis?",{"text":121,"@type":113},"Key challenges include improving the accuracy of ctDNA sequencing tests, reducing the sequencing workload for large numbers of samples, and controlling variables when evaluating the relationship between ctDNA concentration and tumor burden.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343103,1790431271,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 14  \nReview  \nCirculating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring  \nJing Yang1, Na Lin1, Miaomiao Niu1, Boshu Yin1  \n1 Department of Clinical laboratory, Fourth People’s Hospital of Jinan, Jinan 250031, China  \nCorrespondence to: Boshu Yin; email: [jnslsykjwsk@jn.shandong.cn](jnslsykjwsk@jn.shandong.cn)  \nKeywords: circulating tumor DNA, hepatocellular carcinoma, early diagnosis, therapeutic efficacy monitoring, high-throughput sequencing  \nReceived: January 19, 2024 Accepted: May 21, 2024 Published: July 19, 2024  \nCopyright: © 2024 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nIn recent years, the detection and analysis of circulating tumor DNA (ctDNA) have emerged as a new focus in the field of cancer research, particularly in the early diagnosis of hepatocellular carcinoma (HCC) and monitoring of therapeutic efficacy. ctDNA, which refers to cell-free DNA fragments released into the bloodstream from tumor cells upon cell death or shedding, carries tumor-specific genetic and epigenetic alterations, thereby providing a non-invasive approach for cancer diagnosis and prognosis. The concentration of ctDNA in the blood is higher compared to that in healthy individuals or other liquid biopsies from early-stage cancers, which is closely associated with the early diagnosis and comprehensive sequencing studies of HCC. Recent studies have indicated that sequential ctDNA analysis in patients receiving primary or adjuvant therapy for HCC can detect treatment resistance and recurrence before visible morphological changes in the tumor, making it a valuable basis for rapid adjustment of treatment strategies. However, this technology is continuously being optimized and improved. Challenges such as enhancing the accuracy of ctDNA sequencing tests, reducing the burden of high-throughput sequencing on a large number of samples, and controlling variables in the assessment of the relationship between ctDNA concentration and tumor burden, need to be addressed. Overall, despite the existing challenges, the examination and analysis of ctDNA have opened up new avenues for early diagnosis and therapeutic efficacy monitoring in hepatocellular carcinoma, expanding the horizons of this field.  \nINTRODUCTION  \nHepatocellular carcinoma (HCC) is one of the leading causes of global cancer-related mortality, constituting a significant portion of liver cancer cases. According to the World Health Organization, there are over 840,000 newly diagnosed cases of liver cancer globally each year, with approximately 780,000 deaths, highlighting the persistently high mortality and incidence rates of liver cancer. Particularly in East Asia and Africa, where the prevalence of hepatitis virus infections is high, the incidence of HCC remains elevated [1–3] . The symptoms of liver cancer in the early stages are often  \nsubtle, leading to the late detection of many patients who miss the optimal window for surgical intervention. The choice of treatment strategies such as surgical resection, radiofrequency ablation, or liver transplantation is often constrained by tumor size, quantity, location, and the patient’s liver function. While these treatment modalities achieve partial efficacy, the overall cure rate is suboptimal due to significant surgical trauma, potential postoperative complications, and high rates of lesion recurrence [4, 5] . For advanced-stage liver cancer patients opting for targeted therapies such as sorafenib, regorafenib, and cabozantinib, although these treatments extend survival and improve quality of life, they fail to  \n11460  \ncompletely eliminate lesions and are plagued","cbCaia9Gm4QnDkjw","https://ap.wps.com/l/cbCaia9Gm4QnDkjw","pdf",1156223,15,"English","# Abstract\n# Introduction","[{\"question\":\"What is circulating tumor DNA (ctDNA) and why is it useful for HCC?\",\"answer\":\"ctDNA refers to cell-free DNA fragments released from tumor cells into the bloodstream. It carries tumor-specific genetic and epigenetic alterations, supporting non-invasive diagnosis, prognosis, and monitoring in hepatocellular carcinoma.\"},{\"question\":\"How does sequential ctDNA analysis help during treatment?\",\"answer\":\"Sequential ctDNA testing in patients receiving primary or adjuvant therapy can detect treatment resistance and recurrence earlier than visible morphological tumor changes, enabling faster adjustment of treatment strategies.\"},{\"question\":\"What challenges remain for ctDNA mutation analysis?\",\"answer\":\"Key challenges include improving the accuracy of ctDNA sequencing tests, reducing the sequencing workload for large numbers of samples, and controlling variables when evaluating the relationship between ctDNA concentration and tumor burden.\"}]","Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring | PDF",1790049889,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2868a27d3200b0ee558654e1775dd411.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/612b1e6892a1c366818f56c1b5aacef2.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2d32d9716e4fe18c3388cc56671df36.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/442898fd4b47207271c52c51db2deb04.webp",980,1268]